Position of Design & Copyright Protection in Pharmaceutical Industry

Q: What is law available for the protection of graphics, contents, visual elements & creativity available on the packing material and novel appearance of the pharma related products.
– Ashok Kumar
A: Except so many other factors, the pharma products are known with their brands and style of packing material. The exclusive, unique & creative designs of the products their containers and packing material play an important role in the recognition of the products which do not only keep the products in a different track from others but contribute to the goodwill of the brands and company also. For such kind of arrangements, the design of the products should be different from others and should be protected by the design registration. Here, the Industrial Design refers to the “Design” defined under the “Design Act, 2000” which is further registered under the same Act. As per the provision of this Act, “design” means only the features of shape, configuration, pattern, ornament or composition of lines or colors applied to any article whether in two dimensional or three dimensional or in both forms, by any industrial process or means, whether manual, mechanical or chemical, separate or combined, which in the finished article appeal to and are judged solely by the eye. The design of any pharma product to be registrable under the act should be new and original.

The copyright protection also has its place in pharma sector in the same way as design does through the protection of graphics, contents, visual elements, text material & creativity available on the packing material of the pharma products. Protecting through copyright registration, one can keep his packing material, outer carton’s design and appearance of pharma related products safe from being infringed which results from unauthorized use, copy or duplication.

Dr. Javed Hasan,
Advocate (High Court, Delhi) Through,
Lex Intellectia Attorneys for, Drugs & IPR Laws
Email : lexintellectia@gmail.com
Phone : 9818522970

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre